Cutler Group’s Alzamend Neuro ALZN Stock Holding History

Cutler Group’s Portfolio ALZN Stock Details ALZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-2	Closed	-$4K	–	5310
2021 Q3	$4K	Buy	+2	New	+$11K	﹤0.01%	4545

Other funds holding ALZN

Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return

RFG Advisory Birmingham, Alabama $6.4B AUM 19.93% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CSS

Cubist Systematic Strategies Stamford, Connecticut $21B AUM 21.48% 1-Year Est. Return

Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Cutler Group's ALZN Position: Q1 2022 in Review

Cutler Group sold out of Alzamend Neuro (ALZN) in Q1 2022, closing a stake of 9 shares — an estimated $23K sold.

Cutler Group first reported a position in ALZN in Q3 2021 and held it in 2 quarters. The position peaked at $23K in Q4 2021. 20 funds tracked by Wall St. Rank hold ALZN as of Q1 2022.

Cutler Group reported no remaining Alzamend Neuro position as of Q1 2022 after selling out during the quarter.
Cutler Group sold 9 Alzamend Neuro shares in Q1 2022, an estimated $23K.
Cutler Group first reported a position in Alzamend Neuro in Q3 2021 and held it in 2 quarters.
Cutler Group's Alzamend Neuro position peaked at $23K in Q4 2021.
20 funds tracked by Wall St. Rank held Alzamend Neuro as of Q1 2022.

Based on Cutler Group's 13F filing for Q1 2022, filed 14 Apr 2022.